Jin Hui Paik

Jin Hui Paik

Auto-generated profile, based on publicly available information

Jin Hui Paik

Department of Emergency Medicine, Inha University School of Medicine, Incheon, Korea

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
HSHo Kyung Sung
Ho Kyung Sung
JPJin Hui Paik
Jin Hui Paik
YLYU JIN LEE
YU JIN LEE
SKSoo Kang
Soo Kang
Sung HK, et al. J Korean Med Sci. 2021 Apr;36(16):e111. https://doi.org/10.3346/jkms.2021.36.e111

15 July 2022 in Medicine
Verified
Journal Article
Open access
SKSinyoung Kim
Sinyoung Kim
DHDAE YOUNG HONG
DAE YOUNG HONG
KLKyeong Ryong Lee
Kyeong Ryong Lee
JPJin Hui Paik
Jin Hui Paik
HJHyun Min Jung
Hyun Min Jung
Acute kidney injury (AKI) is a common complication in patients with sepsis. We evaluated the potential prognostic value of plasma presepsin to predict AKI in patients with sepsis in the emergency department. A total of 193 patients diagnosed with sepsis based on the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) were included in this observational study. AKI was defined according to the Kidney Disease Improving Global Outcomes clinical practice guideline. Plasma presepsin levels were measured on admission to the emergency department. We compared plasma presepsin levels between patients who did and those who did not develop AKI. AKI occurred in 100 (51.8%) patients. The median plasma presepsin level was significantly higher in patients with AKI than in those without AKI (1061 pg/mL vs 495 pg/mL, P <.001). Plasma presepsin levels were significantly increased in patients with AKI stage 3 compared with those with AKI stages 1 and 2 (P =.001). The area under the curve of presepsin for predicting AKI was 0.793 (95% confidence interval: 0.729–0.848). The optimal presepsin cutoff value for predicting AKI was >572 pg/mL, with a sensitivity of 77.0% and specificity of 81.7%. Plasma presepsin level is a valuable biomarker for the prediction of AKI in patients with sepsis in the emergency department.

13 August 2021 in Medicine
Verified
Journal Article
Open access
SKSoo Kang
Soo Kang
TATae Kyu Ahn
Tae Kyu Ahn
YSYoung Ho Seo
Young Ho Seo
YSYoung Ju Suh
Young Ju Suh
JPJin Hui Paik
Jin Hui Paik
Infectious disease pandemics has a great impact on the use of medical facilities. The purpose of this study was to analyze the effects of coronavirus disease 2019 (COVID-19) on the use of emergency medical facilities in the Republic of Korea. This single-center, retrospective observational study was conducted in a tertiary teaching hospital located in Incheon Metropolitan City, Republic of Korea. We set the pandemic period as February 19, 2020 to April 18, 2020, and the control period was set to the same period in 2018 and 2019. All consecutive patients who visited the emergency department (ED) during the study period were included. Patients were divided into 3 groups according to age (pediatric patients, younger adult patients and older adult patients). The total number, demographics, clinical data, and diagnostic codes of ED patients were analyzed. The total number of ED patients in the pandemic period was lower than that in the control period, which was particularly pronounced for pediatric patients. The proportion of patients who used the 119 ambulances increased in all 3 groups (P = .002, P < .001, and P = .001), whereas the proportion of patients who visited on foot was decreased (P = .006, P < .001, and P = .027). In terms of diagnostic codes, a significant decrease was observed in the proportion of certain infectious or parasitic diseases (A00-B99), and respiratory diseases (J00-J99) in the pediatric and younger adult patient groups (P < .001 and P < .001, respectively). The COVID-19 pandemic reduced the number of ED patients; however, the proportion of patients using ambulances increased. In particular, the proportion of patients with diagnostic codes for infectious and respiratory diseases significantly decreased during the pandemic period.

22 October 2022 in Medicina
Verified
Journal Article
Open access
PDF file
KLKyeong Ryong Lee
Kyeong Ryong Lee
DHDAE YOUNG HONG
DAE YOUNG HONG
JPJin-Hui Paik
Jin-Hui Paik
HJHyun-Min Jung
Hyun-Min Jung
Background and Objectives: Presepsin (PSS) is an independent predictor for estimating disease severity and prognosis in septic patients. Few studies have reported the associations between plasma PSS and the severity and prognosis in patients with community-acquired pneumonia (CAP). We investigated whether a high plasma PSS level was associated with 30-day mortality in CAP patients. Materials and Methods: This retrospective single-center study was conducted in an emergency department. The PSS level was measured in 211 adult CAP patients admitted to the hospital and followed for up to 30 days. We recorded the pneumonia severity index (PSI) and the CURB-65 score. The primary outcome was death from any cause within 30 days. Results: The plasma PSS levels were significantly elevated in the high-risk group (PSI > 130) compared with the low- (PSI < 91) or moderate-risk groups (PSI 91–130). Forty-four patients (20.9%) died within 30 days of admission. Non-survivors had significantly higher plasma PSS levels than survivors among CAP patients: 1083 (697–1736) pg/mL vs. 385 (245–554) pg/mL (p < 0.001). The area under the curve (AUC) to predict 30-day mortality was highest for PSS (0.867), followed by procalcitonin (0.728) and lactate (0.616). The cutoff level of plasma PSS for 30-day mortality was >754 pg/mL. The combination of PSI and plasma PSS level improved the predictive ability for 30-day mortality (AUC = 0.892). Cox regression analysis showed that higher PSS levels (>754 pg/mL) and higher PSI (>126) were associated with 30-day mortality in CAP patients (hazard ratios of 19.472 and 6.375, respectively). Conclusion: Elevated plasma PSS is associated with severity and 30-day mortality in hospitalized CAP patients. Combining plasma PSS level and PSI could significantly improve the predictive ability of PSS for 30-day mortality.

13 November 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Hee Young LEEHee Young LEE
Hee Young LEE
SKSoo Kang
Soo Kang
JPJin-Hui Paik
Jin-Hui Paik
TATae-Kyu Ahn
Tae-Kyu Ahn
YSYoung-Ho Seo
Young-Ho Seo
YLYoonsuk Lee
Yoonsuk Lee
Background: Hyperbaric oxygen therapy (HBOT) involves inhaling nearly 100% oxygen in a pressurized environment and is commonly used to treat various diseases and injuries. Despite its well-known safety, HBOT is associated with side effects, with frequent middle ear barotrauma (MEB) and oxygen toxicity. Understanding the characteristics and risk factors associated with these side effects is critical for improving patient compliance and treatment outcomes. Methods: This retrospective multicenter study aimed to analyze the characteristics and factors associated with side effects during HBOT using a computer-controlled pressurized monoplace hyperbaric chamber. We conducted a retrospective observational study across the two tertiary hospitals in Korea, involving patients who received HBOT from October 2016 for one hospital and October 2017 for another hospital to June 2020. Data were extracted from electronic medical records and hyperbaric chamber logs, including patient demographics, medical history, HBOT indications, and details of side effects. Statistical analyses, including chi-square and t-tests, were used to compare variables. Results: A total of 247 patients (mean age: 59.35 ± 15.05 years, 63.56% male) were included. The most common indications for HBOT were sudden sensorineural hearing loss (27.94%) and post-graft/flap (24.29%). Hypertension (46.15%) and diabetes mellitus (39.27%) were the most frequent comorbidities. Otalgia was the most prevalent side effect (33.20%), followed by chest discomfort (2.02%) and headache (1.62%). A significant proportion of patients (11.74%) terminated HBOT due to side effects, with most pauses occurring at pressures between 1.2 and 1.4 ATA (26.67%). Side effects, particularly otalgia, significantly impact patient compliance with HBOT. Conclusions: The incidence of side effects varies by pressure level during treatment, suggesting the need for tailored strategies to minimize side effects. This study highlights the importance of patient monitoring and education to improve the safety and efficacy of HBOT in monoplace chambers.

16 October 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
Hee Young LEEHee Young LEE
Hee Young LEE
SKSoo Kang
Soo Kang
JPJin-Hui Paik
Jin-Hui Paik
TATae-Kyu Ahn
Tae-Kyu Ahn
YSYoung-Ho Seo
Young-Ho Seo
YLYoonsuk Lee
Yoonsuk Lee
Hyperbaric oxygen therapy (HBOT) involves inhaling nearly 100% oxygen in a pressurized environment and is commonly used to treat various diseases and injuries. Despite its well-known safety, HBOT is associated with complications, with frequent middle ear barotrauma (MEB) and oxygen toxicity. Understanding the characteristics and risk factors associated with these complications is critical for improving patient’s compliance and treatment outcomes. This retrospective multicenter study aimed to analyze the characteristics and factors associated with complications during HBOT using a computer-controlled pressurized monoplace hyperbaric chamber. We conducted a retrospective observational study across two tertiary hospitals in Korea, involving patients who received HBOT from October 2017 to June 2020. Data were extracted from electronic medical records and hyperbaric chamber logs, including patient demographics, medical history, HBOT indications, and details of complications. Statistical analyses, including chi-square and t-tests, were used to compare variables. A total of 247 patients (mean age: 59.35 ± 15.05 years, 63.56% male) were included. The most common indications for HBOT were sudden sensorineural hearing loss (27.94%) and post-graft/flap (24.29%). Hypertension (46.15%) and diabetes mellitus (39.27%) were the most frequent comorbidities. Otalgia was the most prevalent side effect (33.20%), followed by chest discomfort (2.02%) and headache (1.62%). A significant proportion of patients (11.74%) terminated HBOT due to complications, with most pauses occurring at pressures between 1.2 to 1.4 ATA (26.67%). Complications, particularly otalgia, significantly impact patient compliance with HBOT. The incidence of complications varies by pressure level during treatment, suggesting the need for tailored strategies to minimize complications. This study highlights the importance of patient monitoring and education to improve the safety and efficacy of HBOT in monoplace chambers.